- Vitamins & Supplements
- Multivitamins
- TestUdpTemporary
- Vitamins A-Z
- Mineral Supplements
- Multivitamins for Age 50+
- banner
- test 98
- Nutritional Drinks
- Adult Daily Nutrition
- Kids Nutrition (2-15 Yrs)
- For Women
- Top Deals in Supplements
- Health Food & Drinks
- Green Tea & Herbal Tea
- Herbal Juice
- Apple Cider Vinegar
- Healthy Snacks
- Protein Supplements
- Whey Protein
- Amino Acids
- Mass Gainers for testing purpose testing
- Workout Essential
- Fat Burners
Movfor Capsule
Prescription Required
Product introduction
Movfor Capsule is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.
Movfor Capsule is used in the treatment of HIV infections
Movfor Capsule is used in the treatment of HIV infections
Uses of Movfor Capsule
Side effects of Movfor Capsule
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Movfor
- Nausea
- Dizziness
- Diarrhea
How to use Movfor Capsule
Take this medicine in the dose and duration as advised by your doctor. Movfor Capsule may be taken with or without food, but it is better to take it at a fixed time.
How Movfor Capsule works
Movfor Capsule is an antiviral medicine. It works by inhibiting the SARS-CoV-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.
Safety advice
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Movfor Capsule. Please consult your doctor.
Pregnancy
CONSULT YOUR DOCTOR
Movfor Capsule may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Breast feeding
UNSAFE
Movfor Capsule is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Driving
CONSULT YOUR DOCTOR
It is not known whether Movfor Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Kidney
SAFE IF PRESCRIBED
Movfor Capsule is safe to use in patients with kidney disease. No dose adjustment of Movfor Capsule is recommended.
Liver
SAFE IF PRESCRIBED
Movfor Capsule is safe to use in patients with liver disease. No dose adjustment of Movfor Capsule is recommended.
What if you forget to take Movfor Capsule?
If you miss a dose of Movfor Capsule, please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Movfor Capsule
₹62.25/Capsule
₹58.9/capsule
5% costlier
Molnudac 200mg Capsule
Zydus Cadila
₹33.23/capsule
41% cheaper
₹40.25/capsule
28% cheaper
₹56.7/capsule
1% costlier
₹46.5/capsule
17% cheaper
Quick tips
- Do not give Movfor Capsule to children and adolescents aged less than 18 years.
- Do not stop taking Movfor Capsule without talking to your doctor first, as it will protect you from becoming severely ill from COVID-19.
- Even after the treatment, continue practicing COVID-appropriate behavior such as wearing a mask, social distancing, and frequent handwashing.
- For individuals with conceiving potential, it is advisable to use contraceptive methods while taking Molnupiravir and for 4 days after the last dose of the medicine.
Fact Box
Chemical Class
Cytosine Nucleotides
Habit Forming
No
Therapeutic Class
ANTI INFECTIVES
Action Class
Antiviral (Non-HIV) drugs
Patient concerns
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Molnupiravir [EMC SmPC]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021. [Accessed 05 Jan. 2022] (online) Available from:
- U.S. Food and Drug Administration: Center for Drug Evaluation and Research FDA Briefing Document, Antimicrobial Drugs Advisory Committee Meeting, November 30, 2021. [Accessed 05 Jan. 2022] (online) Available from:
- Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high risk of disease progression including hospitalization or death. Cipla: Press Statement. [Accessed 05 Jan. 2022] (online) Available from:
- Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India. Sun Pharma: Press Release. [Accessed 05 Jan. 2022] (online) Available from:
- Molnupiravir. U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee November 30, 2021. [Accessed 05 Jan. 2022] (online) Available from:
- EUnetHTA Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2020. Report No.: RCR19, v1.0. [Accessed 05 Jan. 2022] (online) Available from:
- Molnupiravir [Package leaflet: Information for the patient]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021. [Accessed 05 Jan. 2022] (online) Available from:
- European Medicines Agency. Assessment Report: Use of molnupiravir for the treatment of COVID-19. [Accessed 05 Jan. 2022] (online) Available from:
- Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746. [Accessed 05 Jan. 2022] (online) Available from:
- FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. December 23, 2021. [Accessed 6th Jan. 2022] (online) Available from:
Marketer details
Name: Hetero Healthcare Limited
Address: S.no: 80-84, Melange towers, PatrikaNagar,Madhapur,Hyderabad. Telangana-500081.
Country of origin: India
Lab tests offered by us
Related/Popular tests
87 people viewed this recentlyMRP
₹2490
Inclusive of all taxes
40.0 capsules in 1 bottle
SOLD OUT
Notify me